BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 130 patients (estimated)
- Sponsors
- Juno Therapeutics, a Subsidiary of Celgene
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), GPRC5D
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1819
- NCT Identifier
- NCT06153251
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.